PTC Therapeutics reports first-quarter 2026 financial results and provides an update on its 2026 revenue outlook. The company says total revenue in the quarter is $273 million, including $226 million of product revenue. PTC also states that it is raising its full-year 2026 guidance, supported by continued commercial progress for its Global Sephience™ (sepiapterin) program.
According to PTC, Global Sephience launch momentum continues, with first-quarter 2026 Sephience revenue of $125 million. The company characterizes this as representing 36% quarter-over-quarter growth. It also outlines 2026 product revenue guidance of $750 million to $850 million, attributing the range to the ongoing Sephience launch momentum.
The reports collectively present PTC’s quarter-by-quarter performance and the company’s expectations for full-year product revenue, while emphasizing Sephience as the main driver of results. All figures are presented by the company in its corporate update and financial reporting materials.
